An aerosol dispensing device for discharging a metered amount of medication-containing aerosol into the mouth of a patient by manual compression thereof, which effectively times the release of the medication containing aerosol to coincide with the onset of inhalation of the patient to more effectively introduce the medication deeply into the patient's lungs.
|
1. An aerosol inhaler device for dispensing a metered amount of medication, including a housing, an air passage defined by said housing, an air inlet in communication with one end of said air passage, a mouthpiece in communication with the other end of said air passage through which a user inhales, and a means selectively actuated for dispensing a metered amount of aerosolized medication into said air passage, wherein the improvement comprises:
a valve disposed in said air passage and normally operative to substantially obstruct airflow by user inhalation through said air passage; and means operative in response to actuation of said means for dispensing the aerosolized medication for permitting said valve to open by user inhalation, whereby unobstructed airflow through said air passage to said mouthpiece in response to inhalation by the user is permitted only in response to dispensinag the medication into said air passage.
3. An aerosol inhaler device for use with a container adapted to dispense a metered amount of aerosolized medication, comprising:
a housing; means defining an air passage within said housing; means associated with said housing for receiving said container to dispense said metered amount of aerosolized medication into said air passage at a predetermined location; a mouthpiece communicative with one end of said air passage through which a user inhales; an air inlet communicative with the opposite end of said air passage; a valve disposed within said air passage and normally operative to substantially obstruct airflow through said air passage when a user inhales through said mouthpiece; and means disposed in operative relation with said container and operative in response to dispensing said aerosolized medication therefrom to permit said valve to open when a user inhales through said mouthpiece, so that unobstructed airflow through said air passage in response to inhalation through said mouthpiece is permitted only in response to dispensing said aerosolized medication into said air passage.
2. An aerosol inhaler device as recited in
4. An aerosol inhaler device as recited in
a lever mounted on the housing; and a stop member at one end of said lever, said stop member being normally operative to retain said valve in its closed attitude, and said lever being selectively operative in response to dispensing medication to disengage said stop member from said valve, thereby permitting said valve to open in response to user inhalation.
5. An aerosol inhaler device as recited in
6. An aerosol inhaler device as recited in
7. An aerosol inhaler device as recited in
8. An aerosol inhaler device as recited in
|
This invention relates generally to an aerosol inhaler used to dispense a measured amount of medication-containing aerosol, and relates more specifically to an aerosol inhaler for timing the release of the medication-containing aerosol to coincide with the inhalation of the user and more efficiently introduce the medication deeply into the lungs of the user.
Aerosolized bronchodilator therapy, wherein a measured amount of medication-containing aerosol is inhaled by an asthmatic patient, is considered the mainstay of therapy for asthma. A long-standing problem of this type of treatment is the proper timing of the release of the bronchodilator medication with respect to the onset of inspiration. If an asthma patient receives most of the aerosolized medication at the onset of inspiration, the medication can be carried deeply into the lungs and thus constitute more effective therapy. In contrast, if the aerosolized medication is dispensed too early or too late with respect to the onset of inspiration, the medication will be sprayed ineffectively into the mouth, or may be inhaled only shallowly, so that the medication is expelled without ever reaching the lungs when the patient exhales. This problem becomes even more apparent when considered in the context of a severe asthma attack, for as bronchoconstriction worsens, the patient's ability to inspire becomes progressively more limited. With such a severely limited airflow, the asthma patient must receive the bronchodilator medication at the very onset of inspiration, or else the limited amount of air able to reach the patient's lungs will not carry the essential medication.
Other inhalers known to the art have not successfully confronted this problem, and, as will be seen, allow a patient to spray the medicine into his mouth out of synchronization with inhalation. For example, U.S. Pat. No. 3,456,646 discloses an aerosol inhaler which comprises a housing, a air passage within the housing, a vane disposed in one end of the air passage, a mouthpiece disposed at the other end of the air passage, and an aerosol container being reciprocally received in said housing, disposed so as to inject a metered amount of medication-containing aerosol into the air passage. In this apparatus, a mechanical linkage activated by the vane prevents the aerosol container from discharging its medication into the air passage so long as the vane is in its normal "closed" position. The user places his mouth on the mouthpiece and inhales, creating a pressure differential which causes the vane to pivot, displacing the mechanism linkage and thereby permitting the aerosol container to reciprocate into the housing and to inject its measured amount of medication into the air passage.
U.S. Pat. No. 3,732,864 discloses another aerosol inhaler which discharges its medicine during the patient's inhalation, the inhalation serving to release a gate which normally blocks actuation of the device. This apparatus is similar to that disclosed in the '646 patent, but with the mechanical linkage eliminated and the gate disposed directly underneath the aerosol container. When the user inhales on the mouthpiece, the gate, which normally restrains the aerosol container in its fully extended attitude, rotates out of the way, thereby permitting the container to reciprocate into the housing and dispense its measured amount of medication.
Both of these prior art inhalers require a predetermined minimum airflow during inhalation before medication can be discharged into the housing for inspiration by the user. Additionally, neither of these prior art inhalers synchronizes the release of the medication with the onset of inhalation, and the inhalers thus are often ineffective in delivering the medicine deep into the lungs. Moreover, since these devices require a certain minimal vacuum and airflow in order to operate the valve mechanism, a severely distressed patient may not be able to generate sufficient suction to operate the inhaler, thereby precluding the very therapy so desperately needed. In addition, if a user is uncertain whether he has succeeded in properly inhaling the medication into his lungs, he may be disposed to discharge the device more than once, which could lead to a dangerous overdosage of the medication.
As will be seen, the invention disclosed herein overcomes these and other problems associated with the conventional aerosol inhaler. Stated in general terms, the aerosol inhaler of the present invention comprises a means for properly timing the release of bronchodilator medication to coincide with the onset of inspiration by the patient. Stated in somewhat greater detail, the present inhaler has an air passage into which medication is introduced from a medication dispenser as the patient inhales air drawn through an air passage. The air passage normally is nearly closed by a valve so that little air enters the passage when the patient begins to inhale. The valve operates in response to the medication dispenser to open the air passage only when medication is dispensed while the patient attempts to inhale, allowing the medication to enter the initial flow of the moving air stream inhaled by the patient.
Stated more specifically, a conventional pressurized aerosol bottle containing bronchodilator medication is mounted reciprocally atop a dispenser housing having an air passage. A mouthpiece is disposed at one end of the air passage, and the other end of the passage constitutes an air inlet. A valve is mounted in the air inlet and is normally held in a closed position by a flange on one end of a lever. Downward pressure on the aerosol bottle applies force against the lever, thereby displacing the flange away from the valve and releasing the valve to rotate freely in response to inhalation by the patient. Thus, as the aerosol bottle is downwardly reciprocated, a metered amount of medication is released into the air passage simultaneous with the sudden rush of air occasioned by the opening of the valve after the patient begins to inhale.
The basic concept of the apparatus is that, instead of the patient having to coordinate breathing and the delivery of the medication into the inhaler, the patient must simply inhale through the device and press the aerosol bottle downwardly, which will simultaneously result in delivering a sudden rush of air and a metered amount of medication into the patient's lungs. The device thereby synchronizes the release of the medication with the very onset of inspiration and thus assures correct dosage and maximal delivery of the medicine in the most efficient manner.
Thus, it is an object of this invention to provide an improved aerosol inhaler for the dispensation of metered amounts of bronchodilator medication.
It is a further object of this invention to provide an aerosol inhaler which provides for the proper timing of the release of the bronchodilator medication to coincide with the onset of inspiration by the patient.
It is another object of this invention to provide an aerosol inhaler which can afford therapy to severely distressed asthmatics who may not be able to generate sufficient vacuum to operate a traditional inhaler.
Another object of this invention is to provide an aerosol inhaler which will reliably deliver medication into the lungs on the first attempt and will thus obviate the necessity for a user to repeat the procedure and risk a possibly dangerous overdosage of the medication.
It is a further object of this invention to provide an inexpensive, durable aerosol inhaler.
Other objects, features, and advantages of the present invention will become apparent upon reading the following specifications when taken in conjunction with the drawing and the appended claims.
FIG. 1 is a side cross-sectional view of an apparatus according to the disclosed embodiment of the present invention.
FIG. 2 is an end elevation view of the apparatus in FIG. 1 as seen from one end of the apparatus.
FIG. 3 is an end elevation view of the apparatus in FIG. 1 as seen from the opposite end from that shown in FIG. 2.
Referring now in more detail to the drawing in which like numerals represent like parts throughout the several views, FIG. 1 shows an aerosol inhaler 10 embodying the principles of the present invention. A housing 11 contains an air passage 12 with a venturi throat 13, one end of the air passage 12 defining an air inlet 14, and the other end of the air passage 12 communicative with a mouthpiece 15. A pipe 17 is vertically disposed within the venturi throat 13 perpendicular to the longitudinal axis of the venturi throat and defines dispensing port 18 located along the longitudinal axis of the venturi throat and disposed on the side of the pipe facing the mouthpiece 15.
A port 20 designed to slidably receive an aerosol dispensing bottle 21 is disposed atop the housing 11 concentrically with pipe 17. The aerosol bottle 21 is conventional to the art and includes a hollow spring-loaded valve stem 22 which, when depressed against spring pressure into the top of the aerosol bottle 21, dispenses a metered amount of aerosolized medication. When the aerosol bottle 21 is inserted into the port 20, the valve steam 22 rests against a support member 23 formed by the bottom of the port. Downward reciprocation of the aerosol bottle 21 forces the valve stem 22 against the support member 23 and depresses the valve stem 22 into the aerosol bottle 21 to dispense a metered dosage of medication. A passage 24 defined by support member 23 and disposed within the pipe 17 opens into the air passage 12 at dispensing port 18 to provide for flow of medication from the valve steam 22 into the air passage 12.
A butterfly valve 25 is mounted within the air inlet 14 for rotation about an eccentric axis 27. It will be appreciated by those skilled in the art that if the butterfly valve were mounted about a central axis, the pressure exerted on the valve by the inhalation force of the user would be equal on either side of the central axis, and the butterfly valve would thereby be impeded from rotating open. By providing an eccentric axis, the pressure exerted on the larger portion of the butterfly valve is greater than that exerted on the smaller portion of the valve, thereby expediting the rotation of the valve. It will also be appreciated that the air passage must be shaped to accommodate the rotation of the butterfly valve about an eccentric axis, since the wider portion of the valve would otherwise bind against the wall of the air passage when rotated to open into an air passage of the same size and shape as the valve. In the closed attitude, butterfly valve 25 rests on a valve seat 26 formed in the housing 11 within the air passage 12 so as to let no more than a minimum of air pass around the valve. A lever 30 is pivotably mounted atop the housing 11 by a hinge 31, and a tension spring 32 urges the lever 30 toward a normal position shown in FIG. 1. When the lever 30 is in its normal position, a flange 33 on the end of the lever 30 engages and retains the butterfly valve 25 in its closed attitude against valve seat 26. The lever 30 has an angled end 35 which, when contacted by the butterfly valve 26 upon the valve's return to its normally closed position, urges the lever upwardly, allowing the butterfly valve to pivot past the lever. Downward reciprocation of the aerosol bottle 21 applies a downward force against the lever 30 at a contact point 36, causing the lever 30 to pivot about its hinge 31 and disengaging the flange 33 from the butterfly valve 25. As the butterfly valve pivots open, stop 38 disposed in the air passage 12 prevents the butterfly valve from rotating past a horizontal position.
To use the apparatus, a user places his lips around the mouthpiece 15 and begins to inhale. The butterfly valve 25 within the air inlet 14 at the opposite end of the air passage 12 is held closed by the flange 33 on the end of the lever 31, and the design of the butterfly valve permits only a small amount of air to leak around the closed valve so that the user must exert negative pressure inside the air passage with his lungs and will be less tempted to use only his mouth muscles as one would in sucking liquids through a straw. As the user exerts this negative pressure with his lungs, he pushes on the aerosol bottle 21 relative to the bottom of the housing 11, reciprocating the aerosol bottle into the housing. This downward reciprocation depresses the valve stem 22 into the aerosol bottle 21, thereby releasing a metered amount of medication into the venturi throat 13 of the air passage 12. As the downward reciprocation of the aerosol bottle 21 into the housing 11 releases the medication, the bottle simultaneously exerts a force on the lever 30 which pivots the lever counterclockwise (as shown in FIG. 1) and disengages the flange 33 from the butterfly valve 25, permitting the valve to pivot freely. As the butterfly valve 25 is released, the negative pressure inside the air passage 12 occasioned by the user's inhalational force exerted on the mouthpiece 15 causes the butterfly valve to pivot open, allowing a sudden rush of air to flow through the air passage. The reduced air pressure within the venturi passage 13 helps to atomize the liquid droplets of medication entering the air stream moving through the air passage 12 and entrains the medication with the air inhaled into the patient's lungs. Since the user is already exerting inhalational force, this sudden, unrestricted air flow carries the aerosolized medication deep into the user's lungs.
Upon completion of administering the dosage, the user readies the apparatus for the next dosage by rotating the butterfly valve 25 toward the closed position with his finger. As the butterfly valve 25 contacts the angled end 36 of the lever 30, the lever is urged upwardly, allowing the butterfly valve to pivot past the lever to contact the valve seat 26. As the butterfly valve 25 pivots past the angled end 36 of the lever 30, spring 32 urges the lever back toward its normal position where flange 33 engages and retains the butterfly valve in its closed attitude against the valve seat 26.
An optional embodiment of the invention comprises a one-way expiratory valve to enable the user to keep his mouth around the mouthpiece pending a second dosage. Such a one-way valve is normally operative to cover vent slots in the housing communicative with the air passage, and selectively operative to uncover the slots. Thus, the user cannot inhale air through the one-way vent during the inhalation process, but can expel air through the vent, thereby retaining the mouthpiece of the device in his mouth pending a second dosage.
Another optional embodiment comprises an electrical or mechanical timer to indicate to the user how long the inhaled breath should be held before expiration. The timer is started by the reciprocation of the aerosol bottle into the housing. The user inhales the aerosolized medication and holds the inhaled breath until a predetermined time has expired, at which time the timer will indicate to the user, by a light-emitting diode or other appropriate signal, that exhalation is appropriate.
Finally, it will be understood that the preferred embodiment of the present invention has been disclosed by way of example and that other modifications may occur to those skilled in the art without departing from the scope and spirit of the appended claims.
Waters, IV, William C., Wilmer, Charles I.
Patent | Priority | Assignee | Title |
10046871, | Oct 29 2014 | Electronic cigarette and fluid dispensing system | |
10130581, | Feb 22 2006 | MannKind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
10130685, | Aug 23 2004 | MannKind Corporation | Diketopiperazine salts for drug delivery and related methods |
10130709, | Jun 17 2011 | MannKind Corporation | High capacity diketopiperazine microparticles and methods |
10143655, | Sep 14 2005 | MannKind Corporation | Method of drug formulation |
10159644, | Oct 26 2012 | MannKind Corporation; TechnoVax, Inc. | Inhalable vaccine compositions and methods |
10172850, | Dec 29 2008 | MannKind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
10201672, | Jun 13 2008 | MannKind Corporation | Dry powder inhaler and system for drug delivery |
10258664, | Oct 24 2011 | MannKind Corporation | Methods and compositions for treating pain |
10307464, | Mar 27 2015 | MannKind Corporation | Use of ultrarapid acting insulin |
10342938, | Jun 13 2008 | MannKind Corporation | Dry powder drug delivery system |
10421729, | Mar 15 2013 | MannKind Corporation | Microcrystalline diketopiperazine compositions and methods |
10561806, | Oct 02 2014 | MannKind Corporation | Mouthpiece cover for an inhaler |
10625034, | Apr 01 2011 | MannKind Corporation | Blister package for pharmaceutical cartridges |
10675421, | Jun 20 2008 | MannKind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
10751488, | Jun 13 2008 | MannKind Corporation | Dry powder inhaler and system for drug delivery |
10792445, | Jul 29 2014 | PARI GmbH Spezialisten fuer effektive Inhalation | Spacer chamber comprising an operating means for an inhaler |
10857310, | Mar 09 2012 | Vectura GmbH | Mixing channel for an inhalation device and inhalation device |
11446127, | Aug 05 2013 | MannKind Corporation | Insufflation apparatus and methods |
11660208, | Sep 18 2009 | SPINAL SURGICAL STRATEGIES, INC. | Bone graft delivery system and method for using same |
5027808, | Oct 31 1990 | Tenax Corporation | Breath-activated inhalation device |
5031610, | May 12 1987 | SEPRACOR INC | Inhalation device |
5040527, | Dec 18 1990 | RESPIRONICS NEW JERSEY, INC | Metered dose inhalation unit with slide means |
5060643, | Aug 07 1990 | Tenax Corporation | Breath-activated inhalation device |
5119806, | May 12 1987 | NEW ENGLAND PHARMACEUTICALS, INC | Inhalation device |
5178138, | Sep 11 1990 | Drug delivery device | |
5224472, | Feb 09 1990 | Solange Quenderff | Inhalation device |
5392768, | Mar 05 1991 | Aradigm Corporation | Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval |
5394866, | Mar 05 1991 | Aradigm Corporation | Automatic aerosol medication delivery system and methods |
5404871, | Mar 05 1991 | Aradigm Corporation | Delivery of aerosol medications for inspiration |
5450336, | Mar 05 1991 | Aradigm Corporation | Method for correcting the drift offset of a transducer |
5485827, | Dec 05 1990 | The General Hospital Corporation | Methods and devices for treating plumonary vasoconstriction and asthma |
5497763, | May 21 1993 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
5497764, | Mar 05 1991 | Aradigm Corporation | Medication cassette for an automatic aerosol medication delivery |
5509404, | Jul 11 1994 | Aradigm Corporation | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values |
5520166, | Mar 05 1991 | Aradigm Corporation | Medication cassette for an automatic aerosol medication delivery system |
5536241, | Dec 05 1990 | General Hospital Corporation, The | Methods and devices for relaxing smooth muscle contractions |
5542410, | Mar 05 1991 | Aradigm Corporation | Delivery of aeerosol medications for inspiration |
5544646, | May 21 1993 | Aradigm Corporation | Systems for the intrapulmonary delivery of aerosolized aqueous formulations |
5570683, | Dec 05 1990 | General Hospital Corporation, The | Methods and devices for treating pulmonary vasoconstriction and asthma |
5598836, | May 26 1995 | RESPIRONICS NEW JERSEY, INC | Metered dose inhalation unit with slide means |
5608647, | Mar 05 1991 | Aradigm Corporation | Method for releasing controlled amount of aerosol medication |
5622162, | Mar 05 1991 | Aradigm Corporation | Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval |
5655516, | Mar 05 1991 | Aradigm Corporation | Delivery of aerosol medications for inspiration |
5709202, | May 21 1993 | Intel Corporation | Intrapulmonary delivery of aerosolized formulations |
5718222, | May 21 1993 | Aradigm Corporation | Disposable package for use in aerosolized delivery of drugs |
5743252, | Mar 05 1991 | Aradigm Corporation | Method for releasing controlled amount of aerosol medication |
5755218, | Mar 05 1991 | Aradigm Corporation | Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval |
5823178, | May 21 1993 | Aradigm Corporation | Disposable package for use in aerosolized delivery of drugs |
5823180, | Apr 03 1995 | General Hospital Corporation, The | Methods for treating pulmonary vasoconstriction and asthma |
5826570, | Mar 05 1991 | Aradigm Corporation | Delivery of aerosol medications for inspiration |
5833066, | Jan 02 1996 | INHALERMATE, L L C | Carrying case for oral and nasal inhalation devices with counting mechanism |
5863563, | Oct 20 1994 | SCHEELE, GEORGE | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
5873359, | Dec 05 1990 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
5896853, | Apr 26 1996 | Consort Medical plc | Controlled flow inhalers |
5904938, | Feb 16 1995 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
6012454, | Apr 28 1989 | Minnesota Mining and Manufacturing Company | Dry powder inhalation device |
6014969, | May 21 1993 | Aradigm Corporation | Disposable package for use in aerosolized delivery of antibiotics |
6063407, | Feb 16 1995 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
6119688, | Aug 26 1991 | 3M Innovative Properties Company | Powder dispenser |
6170482, | Mar 03 1997 | Consort Medical plc | Inhalation apparatus |
6269810, | Mar 05 1998 | ZIVENA, INC | Pulmonary dosing system and method |
6427683, | Jan 17 1997 | Aerosol inhaler device | |
6453900, | Jun 09 2000 | SP Medical LLC | Inhaler device |
6475796, | May 20 1999 | Scios INC | Vascular endothelial growth factor variants |
6606992, | Jun 30 1999 | Novartis Pharma AG | Systems and methods for aerosolizing pharmaceutical formulations |
6655379, | Mar 16 1998 | Novartis Pharma AG | Aerosolized active agent delivery |
6805118, | Mar 05 1998 | ZIVENA, INC | Pulmonary dosing system and method |
6887848, | May 20 1999 | Scios, Inc. | Vascular endothelial growth factor variants |
7185651, | May 14 2003 | Novartis Pharma AG | Flow regulator for aerosol drug delivery and methods |
7464706, | Jul 23 1999 | MannKind Corporation; ManKind Corporation | Unit dose cartridge and dry powder inhaler |
7488804, | Feb 02 2005 | REGENTS OF THE UNIVERISITY OF CALIFORNIA, THE | Modified fusion molecules for treatment of allergic disease |
8156936, | Jul 23 1999 | MannKind Corporation | Unit dose capsules and dry powder inhaler |
8215300, | Jul 23 1999 | MannKind Corporation | Unit dose cartridge and dry powder inhaler |
8408200, | Oct 09 1998 | Novartis AG | Flow resistance modulated aerosolized active agent delivery |
8671937, | Jul 23 1999 | MannKind Corporation | Unit dose capsules and dry powder inhaler |
8757169, | Dec 29 2010 | Electronic cigarette refilling apparatus | |
8950397, | Jul 23 1999 | MannKind Corporation | Unit dose cartridge and dry powder inhaler |
8961992, | Apr 02 2014 | TUNITAS THERAPEUTICS, INC | Epsigam fusion protein |
9061111, | Jul 23 1999 | MannKind Corporation | Unit dose capsules and dry powder inhaler |
9109030, | Apr 02 2014 | TUNITAS THERAPEUTICS, INC. | Epsigam fusion protein |
9192675, | Jun 13 2008 | MannKind Corporation | Dry powder inhaler and system for drug delivery |
9220687, | Dec 29 2008 | MannKind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
9233159, | Oct 24 2011 | MannKind Corporation; Torrey Pines Institute for Molecular Studies | Methods and compositions for treating pain |
9241903, | Feb 22 2006 | MannKind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
9283193, | Sep 14 2005 | MannKind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
9339615, | Jun 13 2008 | MannKind Corporation | Dry powder inhaler and system for drug delivery |
9346766, | Aug 20 2004 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
9364436, | Jun 17 2011 | MannKind Corporation | High capacity diketopiperazine microparticles and methods |
9364619, | Jun 20 2008 | MannKind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
9446001, | Sep 14 2005 | MannKind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
9446133, | Jun 13 2008 | MannKind Corporation | Dry powder inhaler and system for drug delivery |
9511198, | Jun 13 2008 | MannKind Corporation | Dry powder inhaler and system for drug delivery |
9610351, | Oct 24 2011 | MannKind Corporation; Torrey Pines Institute for Molecular Studies | Methods and compositions for treating pain |
9630930, | Jun 12 2009 | MannKind Corporation | Diketopiperazine microparticles with defined specific surface areas |
9655850, | Dec 29 2008 | MannKind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
9662461, | Jun 13 2008 | MannKind Corporation | Dry powder drug delivery system and methods |
9675674, | Aug 23 2004 | MannKind Corporation | Diketopiperazine salts for drug delivery and related methods |
9700690, | Mar 20 2002 | MannKind Corporation | Inhalation apparatus |
9706944, | Nov 03 2009 | MannKind Corporation | Apparatus and method for simulating inhalation efforts |
9717689, | Sep 14 2005 | MannKind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
9796688, | Aug 20 2004 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
9801925, | Jun 29 1999 | MannKind Corporation | Potentiation of glucose elimination |
9802012, | Jul 12 2012 | MannKind Corporation | Dry powder drug delivery system and methods |
9802013, | Mar 10 2005 | MEDSPRAY XMEMS BV | Inhaler with a mixing channel for producing an aerosol to be inhaled |
9925144, | Jul 18 2013 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
9943571, | Aug 11 2008 | MannKind Corporation | Use of ultrarapid acting insulin |
9983108, | Mar 11 2009 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
D368364, | Feb 02 1995 | Inhaler case |
Patent | Priority | Assignee | Title |
3456646, | |||
3789843, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Date | Maintenance Fee Events |
Dec 04 1989 | M273: Payment of Maintenance Fee, 4th Yr, Small Entity, PL 97-247. |
Dec 12 1989 | ASPN: Payor Number Assigned. |
Dec 23 1993 | M284: Payment of Maintenance Fee, 8th Yr, Small Entity. |
Dec 23 1993 | M286: Surcharge for late Payment, Small Entity. |
Jan 10 1994 | ASPN: Payor Number Assigned. |
Jan 10 1994 | RMPN: Payer Number De-assigned. |
Feb 14 1998 | REM: Maintenance Fee Reminder Mailed. |
May 31 1998 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Jun 03 1989 | 4 years fee payment window open |
Dec 03 1989 | 6 months grace period start (w surcharge) |
Jun 03 1990 | patent expiry (for year 4) |
Jun 03 1992 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jun 03 1993 | 8 years fee payment window open |
Dec 03 1993 | 6 months grace period start (w surcharge) |
Jun 03 1994 | patent expiry (for year 8) |
Jun 03 1996 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jun 03 1997 | 12 years fee payment window open |
Dec 03 1997 | 6 months grace period start (w surcharge) |
Jun 03 1998 | patent expiry (for year 12) |
Jun 03 2000 | 2 years to revive unintentionally abandoned end. (for year 12) |